Administering SP-D therapeutically resulted in a significant decrease in specific IgE and IgG1 levels, as well as reductions in peripheral blood eosinophilia and pulmonary infiltration, particularly in a murine model of allergic bronchopulmonary aspergillosis (ABPA) using BALB/c mice (100). Here, SFTPD is linked to allergic bronchopulmonary aspergillosis.